Articles
Pharmacy Outlook: Susan Cantrell, AMCP (1/6, Susan Cantrell, Chain Drug Review) comments “...A welcome health care trend for the upcoming year is the continuing realignment of care from volume-based to value-based. For decades, we have operated under a fee-for-service model, charging by doctor’s visits, filled prescriptions and per procedure. In shifting to a value-based care model, which rewards the use of medications and treatments that lead to better patient outcomes, providers are able to better serve patients holistically and preventatively while increasing affordability. Harnessing and analyzing health data to demonstrate outcomes and comparative effectiveness relative to other medicines optimizes patient outcomes, avoids expensive unnecessary prescriptions, helps reduce costs to our health care system and promotes use of the right medicine at the right time.” Full
How Can State Legislation Promote Value In Health Care? Three Innovative Models (1/6, Roslyn Murray, Suzanne F. Delbanco and Jaime S. King, Health Affairs Blog) comments “...COVID-19 may create new opportunities for payment innovation, as providers look for effective ways to protect their revenue when patient use is declining. A small number of states have made progress in advancing VBP through legislation that creates Medicaid ACOs or gives regulatory entities greater flexibility to innovate. These initiatives can serve as helpful models for new state efforts to support the sustainability of physician practices, ease the pandemic-induced strain on state budgets, and improve health care value for all who use and pay for health care services.” Full
Press Releases
Treatment for Men with Enlarged Prostate Is Recommended by NICE for NHS Adoption (1/6, NICE Press Release) “...The PLASMA system uses electrodes to cut out prostate tissue and stop any local bleeding afterwards. Clinical outcomes are the same as the conventional monopolar transurethral resection of the prostate (mTURP), but PLASMA avoids the risk of transurethral resection syndrome and reduces the need for blood transfusion and the length of hospital stay. This means that the treatment costs are less than for mTURP – saving hospitals up to £534 per procedure.” Full
Journals
Edoxaban Versus Warfarin on Stroke Risk in Patients with Atrial Fibrillation: A Territory-Wide Cohort Study Dicken Kong, et al. January 5, 2021 medRxiv